German Speaking Mycological Society Research Articles

S1 Guideline onychomycosis.

Onychomycosis is a fungal infection of the fingernails and toenails. In Europe, tinea unguium is mainly caused by dermatophytes. The diagnostic workup comprises microscopic examination, culture and/or molecular testing (nail scrapings). Local treatment with antifungal nail polish is recommended for mild or moderate nail infections. In case of moderate to severe onychomycosis, oral treatment is recommended (in the absence of contraindications). Treatment should consist of topical and systemic agents. The aim of this update of the German S1 guideline is to simplify the selection and implementation of appropriate diagnostics and treatment. The guideline was based on current international guidelines and the results of a literature review conducted by the experts of the guideline committee. This multidisciplinary committee consisted of representatives from the German Society of Dermatology (DDG), the German-Speaking Mycological Society (DMykG), the Association of German Dermatologists (BVDD), the German Society for Hygiene and Microbiology (DGHM), the German Society of Pediatric and Adolescent Medicine (DGKJ), the Working Group for Pediatric Dermatology (APD) and the German Society for Pediatric Infectious Diseases (DGPI). The Division of Evidence-based Medicine (dEBM) provided methodological assistance. The guideline was approved by the participating medical societies following a comprehensive internal and external review.

State of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul-Ehrlich-Society for Chemotherapy (PEG).

Little is known about the infrastructure to translate advances in the management of patients at risk to develop invasive opportunistic fungal diseases. To assess the current state of Medical Mycology support in Germany, we conducted a survey among all 36 academic medical centres. The survey consisted of a 3-pages questionnaire sent out in the first half of 2019. Information included details of infrastructure, education and teaching; consultation services and interdisciplinary conferences; research activities and participation in network groups; radiology, microbiology and pharmacology support; publication activity; and European Confederation for Medical Mycology (ECMM) Excellence Center designation, if assigned. Information was returned from 24 centres (67%). Thirteen institutions (54%) reported an independent infectious disease, and two a separate Medical Mycology department (8%); a Medical Mycology working group was reported for nine institutions (38%). An infectious disease consultation service was existent in 16 institutions (67%) and a multidisciplinary conference in 13 (54%). Fifteen institutions reported a separate study office with activities in infectious disease studies (63%). Laboratory capability for fungal identification and susceptibility testing was confirmed by all 24 institutions; testing of galactomannan by 23 (96%), cryptococcal antigen by 21 (88%), ß-D-Glucan by 9 (38%), and panfungal and Pneumocystis PCR by 21 and 22 (88% and 92%), respectively. Therapeutic drug monitoring of voriconazole was reported to be available in 15 (63%) institutions with a turnaround of ≤24h during weekdays in 10 (42%). Two of the 24 University hospitals (8%) reported ECMM Diamond Excellence Status. The results of this survey document the continuing need to improve the availability of specialised Medical Mycology support in German academic medical centres.

S1 guidelines: Tinea capitis.

Tinea capitis describes a dermatophyte infection of scalp and hair that predominately occurs in children. The diagnostic workup includes microscopic examination, culture and/or molecular tests. Treatment is guided by the specific organism involved and should consist of systemic agents as well as adjuvant topical treatment. The aim of the present update of the interdisciplinary German S1 guidelines is to provide dermatologists, pediatricians and general practitioners with a decision tool for selecting and implementing appropriate diagnostic and therapeutic measures in patients with tinea capitis. The guidelines were developed based on current international guidelines, in particular the 2010 European Society for Pediatric Dermatology guidelines and the 2014 British Association of Dermatologists guidelines, as well as on a review of the literature conducted by the guideline committee. This multidisciplinary committee consists of representatives from the German Society of Dermatology (DDG), the German-Speaking Mycological Society (DMykG), the German Society for Hygiene and Microbiology (DGHM), the German Society of Pediatric and Adolescent Medicine (DGKJ) and the German Society for Pediatric Infectious Diseases (DGPI). The Division of Evidence-based Medicine (dEBM) provided methodological assistance. The guidelines were approved by the participating medical societies following a comprehensive internal and external review.

Abstracts of the 48th Annual Meeting of the German-Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ŌGMM), 4-6 September 2014, Salzburg, Austria.

Abstracts of the 48th Annual Meeting of the German-Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ŌGMM), 4-6 September 2014, Salzburg, Austria.

Author Index

MycosesVolume 57, Issue s2 p. 45-46 Author IndexFree Access Author Index First published: 04 September 2014 https://doi.org/10.1111/myc.12218AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume57, Issues2Special Issue: Abstracts of the 48th Annual Meeting of the German-Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ŌGMM), 4–6 September 2014, Salzburg, AustriaSeptember 2014Pages 45-46 RelatedInformation

Author Index

MycosesVolume 56, Issue s2 p. 29-30 Author IndexFree Access Author Index First published: 12 August 2013 https://doi.org/10.1111/myc.12117AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume56, Issues2Special Issue: Abstracts of the 47th Annual Meeting of the German-Speaking Mycological Society (DMykG), 5–7 September 2013, Tübingen, GermanySeptember 2013Pages 29-30 RelatedInformation

Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy

Invasive Candida infections are important causes of morbidity and mortality in immunocompromised and hospitalised patients. This article provides the joint recommendations of the German-speaking Mycological Society (Deutschsprachige Mykologische Gesellschaft, DMyKG) and the Paul-Ehrlich-Society for Chemotherapy (PEG) for diagnosis and treatment of invasive and superficial Candida infections. The recommendations are based on published results of clinical trials, case-series and expert opinion using the evidence criteria set forth by the Infectious Diseases Society of America (IDSA). Key recommendations are summarised here: The cornerstone of diagnosis remains the detection of the organism by culture with identification of the isolate at the species level; in vitro susceptibility testing is mandatory for invasive isolates. Options for initial therapy of candidaemia and other invasive Candida infections in non-granulocytopenic patients include fluconazole or one of the three approved echinocandin compounds; liposomal amphotericin B and voriconazole are secondary alternatives because of their less favourable pharmacological properties. In granulocytopenic patients, an echinocandin or liposomal amphotericin B is recommended as initial therapy based on the fungicidal mode of action. Indwelling central venous catheters serve as a main source of infection independent of the pathogenesis of candidaemia in the individual patients and should be removed whenever feasible. Pre-existing immunosuppressive treatment, particularly by glucocorticosteroids, ought to be discontinued, if feasible, or reduced. The duration of treatment for uncomplicated candidaemia is 14 days following the first negative blood culture and resolution of all associated symptoms and findings. Ophthalmoscopy is recommended prior to the discontinuation of antifungal chemotherapy to rule out endophthalmitis or chorioretinitis. Beyond these key recommendations, this article provides detailed recommendations for specific disease entities, for antifungal treatment in paediatric patients as well as a comprehensive discussion of epidemiology, clinical presentation and emerging diagnostic options of invasive and superficial Candida infections.

Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009

The objectives of this study were to identify unsolved issues in the management of invasive candidiasis, identify controversies and achieve consensus. The German Speaking Mycological Society (Deutschsprachige Mykologische Gesellschaft, DMykG e.V.) asked other German infectious diseases (ID) and mycological societies to submit unsolved issues concerning the diagnosis and treatment of fungal infections. Based on these contributions, a digital web-based questionnaire of 12 questions on Candida infections was designed to be completed by experts of the participating societies. Controversial results were identified by a mathematical model and were discussed at a consensus conference during the 43rd Annual Meeting of the DMykG e.V. in Cologne, Germany. Forty-two individuals completed the questionnaire. Analysis showed a strong consensus on treatment indications, choice of antifungals for clinical situations, handling of central venous catheters, duration of treatment and role of susceptibility testing. Opinions diverged on: initial treatment of haemodynamically stable neutropenic and haemodynamically unstable non-neutropenic patients, step down to oral treatment and the differential role of the echinocandins. These questions were presented for discussion at the expert consensus conference. In three of four questions, consensus was achieved. A two-step approach - web-based survey plus classical panel discussion - allows to capture expeditiously the opinions of a large and diverse group of individuals, to identify controversial issues and to resolve them in a personal, interactive setting. Thus, expert consensus was achieved on nine of 12 important questions on how to treat invasive candidiasis.

Current issues in the clinical management of invasive aspergillosis – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009

The objectives of this study were to identify unsolved issues in the management of invasive aspergillosis, identify controversies and achieve consensus. The German Speaking Mycological Society (Deutschsprachige Mykologische Gesellschaft, DMykG) invited other German infectious diseases (ID) and mycological societies to submit unsolved issues concerning the diagnosis and treatment of invasive aspergillosis. Based on these contributions, a digital web-based questionnaire of 12 questions on Aspergillus spp. was designed to be completed by experts of the participating societies. Controversial results were identified by a mathematical model and were discussed at a consensus conference during the 43rd Annual Meeting of the DMykG in Cologne, Germany. Forty-two individuals completed the questionnaire. Analysis showed a strong consensus on effective preventive measures, choice of antifungal agents for pre-emptive, empiric and targeted treatment, as well as the evaluation of early chest CT control scans as a measure of treatment response assessment. Opinions on the indication for a pulmonary biopsy of a halo sign in high-risk neutropenic patients and on the role of Aspergillus spp. PCR as well as galactomannan from serum in the assessment of treatment duration diverged in spite of discussion such that a consensus could not be reached. Using a recently published two-step approach - web-based survey plus classical panel discussion - expert consensus was achieved on 10 of 12 questions concerning the diagnosis and treatment of invasive aspergillosis.

44th Annual Meeting of the German-Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ÖGMM)

44th Annual Meeting of the German-Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ÖGMM)

42nd Annual Meeting of the German–Speaking Mycological Society (DMykG)

MycosesVolume 51, Issue 5 p. 365-436 42nd Annual Meeting of the German–Speaking Mycological Society (DMykG) First published: 12 August 2008 https://doi.org/10.1111/j.1439-0507.2007.01598.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume51, Issue5September 2008Pages 365-436 RelatedInformation

41st Annual Meeting of the German?Speaking Mycological Society (DMykG)

MycosesVolume 50, Issue 5 p. 334-382 41st Annual Meeting of the German–Speaking Mycological Society (DMykG) First published: 10 August 2007 https://doi.org/10.1111/j.1439-0507.2007.01430_2.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Volume50, Issue5September 2007Pages 334-382 RelatedInformation

40th Annual Meeting of the German‐Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ÖGMM)

MycosesVolume 49, Issue 5 p. 352-382 40th Annual Meeting of the German-Speaking Mycological Society (DMykG) together with the Austrian Society of Medical Mycology (ÖGMM) First published: 08 August 2006 https://doi.org/10.1111/j.1439-0507.2006.01277.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume49, Issue5September 2006Pages 352-382 RelatedInformation

16thConference of the Working Group “Mycologic Laboratory Diagnostics” of the German-Speaking Mycological Society (DMykG) on November 5th2004 in Leipzig

Die 16. Tagung der Arbeitsgruppe „Mykologische Laboratoriumsdiagnostik” der Deutschsprachigen Mykologischen Gesellschaft fand 2004 zum mittlerweile vierten Mal in Leipzig statt. Fast 60 Teilnehmer - Hautärzte, Mikrobiologen und Naturwissenschaftler, jedoch auch MTA aus mykologischen und mikrobiologischen Laboratorien sowie Hautarztpraxen - waren der Einladung gefolgt. Im Mittelpunkt der Tagung standen die Schimmelpilze, welche im weiten Feld der Mikrobiologie, aber auch der Mykologie im engeren Sinne, häufig vernachlässigt werden. Es ging um seltene Erreger - sog. emerging pathogens - und um die nach wie vor schwierig zu interpretierende, aber mittlerweile anerkannte serologische Diagnostik der Aspergillosen mittels Antigennachweis. Weiteres Thema war die Histopathologie als ein vielleicht sogar wesentlicher Pfeiler in der Diagnostik invasiver Schimmelpilzinfektionen.

15th Meeting of the Work Team „Mycological Laboratory Diagnostics” in the German-Speaking Mycological Society (DMykG) at Leipzig on 16 th November 2001

Am 16. November 2001 fand in Leipzig die 15. Tagung der Arbeitsgemeinschaft „Mykologische Laboratoriumsdiagnostik” der Deutschsprachigen Mykologischen Gesellschaft (DMykG) statt. Damit war Leipzig nach dem Jahr 2000 erneut Tagungsort, und mit in diesem Jahr ca. 100 Teilnehmern aus dem gesamten Bundesgebiet war die Tagung sowie der anschließende Kurs zur Differenzierung von Dermatophyten und Dermatophyten-ähnlichen Schimmelpilzen mehr als ausgebucht. Der Kurs wurde, um allen Tagungsteilnehmern die praktischen Übungen zu ermöglichen, von Herrn Dr. H. P. Seidl aus München dankenswerterweise zweimal durchgeführt.

In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.

In vitro susceptibilities were determined for a total of 159 clinical isolates and 12 reference strains of yeasts belonging to different Candida species including 94 Candida albicans strains, and further genera such as Cryptococcus, Trichosporon, Geotrichum and Saccharomyces. Minimum inhibitory concentration (MIC) values for fluconazole and itraconazole were assessed using a microdilution technique with the semisynthetic high resolution (HR) medium supplemented with glucose and asparagine but without sodium hydrogen carbonate (pH 7.0), according to a proposal of the working group 'Clinical Mycology' of the German Speaking Mycological Society. Fluconazole MIC values for C. albicans were between 0.125 and > or = 128 micrograms ml-1. Thus, the median of 1 microgram ml-1 showed that the overall fluconazole susceptibility was good. As expected, Candida krusei (seven strains) exhibited diminished in vitro susceptibility with MIC values for fluconazole of 8 to 128 micrograms ml-1 with a median of 64 micrograms ml-1. Some Candida kefyr strains seemed to be less susceptible against fluconazole which was indicated by a MIC90 of 64 micrograms ml-1. Surprisingly, no Candida glabrata isolate exhibited a MIC value greater than 16 micrograms ml-1. Other Candida species, Trichosporon cutaneum, Geotrichum candidum and Saccharomyces cerevisiae showed low MICs to fluconazole. In vitro susceptibility testing of itraconazole revealed that all Candida species except C. albicans, but also Trichosporon cutaneum, Geotrichum candidum, and Saccharomyces cerevisiae exhibited acceptable low MIC values against itraconazole (0.03-2 micrograms ml-1). Their MIC90 values for itraconazole were in the close range between 0.125 and 2 micrograms ml-1. MIC values between 0.125 and 2 micrograms ml-1 were obtained, even for C. krusei strains. On the other hand, the range of C. albicans MICs was between 0.0125 and > or = 16 micrograms ml-1 with MIC50 and MIC90 values of 0.125 and > or = 16 micrograms ml-1, respectively, indicating that a considerable number of yeast strains have high MICs. The comparative evaluation of different experimental conditions revealed that there exists a marked influence both of inoculum size and incubation time on the results of susceptibility testing. Therefore, for routine usage 10(2) CFU ml-1 and 18-24 h incubation time for this microdilution method with HR medium are recommended.

Susceptibility testing of fluconazole: evaluation of a multicenter study of the working group "Clinical Mycology" of the German Speaking Mycological Society

In a collaborative study for in vitro testing of fluconazole against clinical yeast isolates participated 21 laboratories of the working group "Clinical Mycology" of the German Speaking Mycological Society. In these centers, according to a standard test protocol 1181 clinical isolates from 1033 patients were tested to their susceptibility against fluconazole by microdilution, agar diffusion and partly by agar dilution. Approximately 600 strains (59.1%) of the collective of 1106 isolates sent to a reference center underwent retesting in one laboratory (center 13). These strains demonstrated almost the same species distribution as the total collective. For 80% of all isolates a MIC of < or = 4 micrograms/ml and for 90% of the Candida albicans strains a MIC of < or = 2 micrograms/ml has been determined. Only approx, 9% of all isolates (4% with Candida albicans) showed a MIC of < or = 25 micrograms/ml. By parallel testing of 10 control strains issued by the reference center to the laboratories, the inter- and intra-laboratory comparability of the susceptibility testing of fluconazole was checked. The results demonstrated that under appropriate technical prerequisites and standardised test conditions, the methods used routinely in bacteriology microdilution, agar dilution and agar diffusion may also be applied in a reproducible way in the routine mycological laboratory for the susceptibility testing of yeasts.

The Twenty‐Fifth Meeting of the German Speaking Mycological Society, Essen, Germany, 29–31 August 1991

MycosesVolume 35, Issue 7-8 p. 201-205 The Twenty-Fifth Meeting of the German Speaking Mycological Society, Essen, Germany, 29–31 August 1991 First published: July 1992 https://doi.org/10.1111/j.1439-0507.1992.tb00847.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume35, Issue7-8July 1992Pages 201-205 RelatedInformation